-
07:58:56 AM

SNDX Stock News

03/15/23 4:05 PM
Nasdaq : SNDX
clinical trial
Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients
Syndax Pharmaceuticals, Inc. today announced that data from the Phase 1 portion of the ongoing Phase 1/ 2 AUGMENT-101 trial of revumenib in patients with nucleophosmin mutant and KMT2A-rearranged relapsed/refractory acute leukemia and an analysis describing MEN1 mutations observed in the study have been published in the journal Nature.
RHEA-AI
neutral
02/28/23 4:03 PM
Nasdaq : SNDX
earnings
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. "With two pivotal data readouts expected later this year and potential regulatory filings to...
RHEA-AI
neutral
12/10/22 5:00 PM
Nasdaq : SNDX
clinical trial
Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting
- 30% CR/CRh rate in efficacy evaluable population; 27% CR/CRh rate observed in both mNPM1 and KMT2Ar (MLLr) R/R acute leukemia patients treated at RP2D --  9 of 12 patients who underwent stem cell transplant after achieving a response with revumenib remained in remission, with four continuing
RHEA-AI
neutral